Evidence map›Paper›PMID 37461333›Full record

ArticleInternational journal of STD & AIDS2023

Lessons learned from U.S. rapid antiretroviral therapy initiation programs.

Rupali K Doshi, Shawnika Hull, Aaron Broun, Saanjh Boyani, Darryl Moch, Adam J Visconti, Amanda D Castel, Stefan Baral, Jonathan Colasanti, Allan E Rodriguez and 3 more

Abstract read
In one paragraph

Article in International journal of STD & AIDS, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rupali K DoshiDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Shawnika HullRutgers University School of Communication and Information, New Brunswick, NJ, USA.
Aaron BrounDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Saanjh BoyaniDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Darryl MochDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID 0000-0002-9431-6553
Adam J ViscontiThe HIV/AIDS, Hepatitis, STD and TB Administration (HAHSTA), District of Columbia Department of Health, Washington, DC, USA.
Amanda D CastelDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Stefan BaralDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Jonathan ColasantiEmory University School of Medicine, Atlanta, GA, USA.
Allan E RodriguezUniversity of Miami Miller School of Medicine, Miami, FL, USA.
Joyce JonesJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Susa CoffeyUniversity of California San Francisco School of Medicine, San Francisco, CA, USA.
Anne K MonroeDepartment of Epidemiology, Milken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID 0000-0003-3201-3845

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI GWENDOLYN Barbara SCOTT · 2007 to 2026
$33.8M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
Pharmacology and Pharmacometrics CoreP30AI168436 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson, Petros C Karakousis · 2022 to 2026
$6.1M
NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI117970NIAID NIH HHS P30 AI168436
6 · The paper itself

Abstract

backgroundRapid antiretroviral therapy initiation (R-ART) for treatment of HIV has been recommended since 2017, however it has not been adopted widely across the US. PURPOSE: The study purpose was to understand facilitators and barriers to R-ART implementation in the U.S. RESEARCH

designThis was a qualitative design involving semi-structured interviews. STUDY SAMPLE: The study sample was comprised of the medical leadership of nine US HIV clinics that were early implementers of R-ART. DATA COLLECTION AND ANALYSIS: In-depth, semi-structured interviews were performed. The Consolidated Framework for Implementation Research (CFIR) was used to guide thematic analysis.

resultsWe identified three main content areas: strong scientific rationale for R-ART, buy-in from multiple key stakeholders, and the condensed timeline of R-ART. The CFIR construct of Evidence Strength and Quality was cited as an important factor in R-ART implementation. Buy-in from key stakeholders and immediate access to medications ensured the success of R-ART implementation. Patient acceptance of the condensed timeline for ART initiation was facilitated when presented in a patient-centered manner, including empathetic communication and addressing other patient needs concurrently. The condensed timeline of R-ART presented logistical challenges and opportunities for the development of intense patient-provider relationships.

conclusionsResults from the analysis showed that R-ART implementation should address the following: 1) logistical planning to implement HIV treatment with a condensed timeline 2) patients' mixed reactions to a new HIV diagnosis and 3) the high cost of HIV medications.

Indexed as

HIV InfectionsCognitionCommunicationHumansPatientsQualitative ResearchCFIRHIV/AIDSimplementationqualitativetreatment initiation

Identifiers

PMID37461333
PMCPMC11000141

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.